Category Archives: What’s Going On

  • -
Palm Beach Event lunch with Charles Laverty

Palm Beach Event Luncheon Event by FON

We are pleased to announce a Palm Beach event luncheon held by Palm Beach Family Office Association.  The event will take place on November 7th at noon at the Flagler Steakhouse.

The event is Transforming Stenting Best Practice in Coronary Bifurcation Disease.   

You may RSVP here.


  • -
Dick Cheney Joining Us At The TCT2018

Dick Cheney Will Be Joining Us At TCT2018

Dick Cheney Joining US

Advanced Bifurcation Systems is sponsoring a booth at the tct2018 convention in San Diego.  We are very honored to have Dick Cheney joining us at our booth.

The event is hosted by the Cardiovasculare Research Foundation.  The dates are Sepember 21st through the 25th.  You can find more information on the event by visiting this link.


  • -
Charles Laverty will present ABS at the Southern California Investor Conference on August 23rd in Newport Beach

ABS Presenting at SoCal Investor Conference August 23rd

Investors and Entrepreneurs provide the Fuel and Spark for Innovation

Our CFO, Ken Richards and other management for ABS will be speaking at this event that will commence at noon this Thursday, August 23rd at the 2018 Southern California Investor Conference at the Balboa Bay Resort in Newport Beach.

Experts predict that the coronary stent market will reach $10B in 2025 and Bifurcation disease could be 25% of that. As Family Office Networks Founder Andrew Schneider announced recently, “We believe ABS is poised to capture a significant part of this $2.5B market as the only true and complete bifurcating stent delivery platform in the market.”

Conference Details

Southern California Investor Conference
12 noon
Thursday, August 23rd
Balboa Bay Resort, Newport Beach

  • -

ABS Announces California Manufacturing Center

Today, Advanced Bifurcation Systems® will launch our global manufacturing facility in Livermore, California. In a blog post and article, this location will create an estimated 35-50 new positions to start at ABS and it will serve as our initial global manufacturing hub.

The facility location has Class 10,000 Cleanrooms which are critical to our plan and will be certified to build and assemble the ABS Platform. Livermore was selected because it h some of the very best facilities in the world and because of its place as a top global hub for talent and innovation in medical devices.


New Heart Technologies in Battle post by Charles Laverty for ABS

Innovative Technologies Fight the World’s Top Killer

Technologies In Battle

Heart disease can strike when least expected. Almost everyone knows someone who has suffered from a heart attack or a stroke. At present, heart disease is still the number one killer in the world. But new technologies hold promise and are likely to revolutionize healthcare.

Mobile health technology is being seen as an affordable way to address risks associated with heart disease such as high blood pressure and excess weight. Studies have shown how patients responded to text messages of advice, support, and motivation, managing to meet their targets faster than control groups.

There is even a smartphone app that is able to measure how much blood the heart pumps with each beat. It can do this as well as an ultrasound.

Analyzing The Eye

Google scientists have found a way to assess the risk of heart disease by using machine learning. They have software that can analyze the back of a patient’s eye and establish the likelihood of a person suffering a cardiac event. This is not being used in clinical settings yet because further research is needed.

The NHS is planning to start using AI to diagnose scans this year. An AI system was developed at John Radcliffe Hospital that makes a possible more accurate diagnosis of scans.

With AI comes the ability to accumulate and analyze great quantities of medical data and improve on existing diagnostic procedures. In turn, patients benefit from receiving the right treatment at the right time which can improve their outlook.

A Simple Day Procedure

Our own dual catheter system has the potential to transform the way bifurcate lesions are treated, turning this into a simple day procedure rather than a complex, risky operation. Once again, the patient will benefit from less downtime and see better results.

The use of these new technologies could have a powerful impact on our lives, increasing life expectancy and reducing heart disease fatalities. They could mean the difference between life and death.


MaRS Accepted ABS Canada

MaRs Accepts Advanced Bifurcation Systems Canada

Accepted by MaRS

ABS is very excited to be accepted to join MaRS.  MaRS helps entrepreneurs grow their companies with a comprehensive network of partners.

A quote from their site is “MaRS is the world’s largest urban innovation hub, a place where today’s moonshots become tomorrow’s breakthroughs. It’s a launchpad for startups, a platform for researchers and a home to innovators.”

This Canada based company is found in one of the largest most diverse city in the country.  They are uniquely located to lead in change.  MaRS brings the communities of researchers, social scientists, business experts, and educators all together.

Our company is proud to join these ranks and our full article can be found here.


Charlie Laverty and Axcessnews

Raising Further Funds Story by Axcessnews

Melissa Thompson of Axcessnews.com did a story ABS on how we are raising more funds for our company.  These funds will in turn, be life saving for a lot of people.

You can read the full article here.


RESI Toronto Innovation Challenge post by Charles Laverty

A Finalist RESI Toronto Innovation Challenge

Been Chosen

Our company is very happy to have been chosen as one of the finalist in this years RESI Toronto Innovation Challenge.

RESI Toronto Innovation Challenge

RESI handpicks businesses that exemplify important sections of the healthcare industry.  This includes diagnostics and digital health, therapeutics and medical devices.  Companies are picked for their technical merit and scientific merit as well as their commercial growth and activity.

RESI website found here.

 


Tech To Manage Heart Disease

New Tech Helps Manage Heart Disease

New Technology to Help with Health

You see a lot of people wearing pieces of technology to help them stay fit.  In staying fit, this in turn, helps people manage heart disease.

Manage Heart Disease Daily

From Fitbits and Garmins to phone apps, these are just a part of the new technology to help people.  We have created a new stent system that is helping people tremendously with their heart disease.

 


Asian Market Strategic Move post by Charles Laverty CEO

Asian Market Sees The Potential

ABS is Making Noise in Asia

We’ve recently begun the next phase of our ongoing growth strategy that will focus on developing plans for the Asian market.  We met with both medical experts and potential investment partners. The trip was a major success.

Cardiovascular illness is the leading cause of death globally and nowhere is this more evident than in Asia. The Western world had long been considered to have the highest incidents of death from heart disease, but that’s simply no longer true.

1 Out Of 5

In China 1 out of every 5 adults has some form of cardiovascular related illness and those numbers are climbing. It’s part of the global pandemic that’s cutting far too many lives short long before their time. A combination of lifestyle changes and improved medical treatments are needed to curve this problem.

While our initial focus in Asia has been on its largest market in China, this is just phase one of our plans to actively seek partnerships in the Asian market. Cardiovascular disease is a problem that the entire region is struggling to cope with. In Japan for example, the number of people suffering from hypertension is increasing steadily.

Raising Additional Funds in the Asian Market

New approaches are necessary and ABS’s innovative stenting system is a prime example. Our method allows for the placement of stents in both the mother and daughter arteries of a bifurcating lesion at the same time. The procedure is simpler, less time consuming, and more affordable than anything being used today.

In the coming months, we expect to begin the application to the FDA and other regulatory bodies.  In turn, we’ll continue to seek out new partners in Asia and around the globe. Our board members have set a goal of raising an additional $20 million in investment to fund this growth and feels like ABS has huge potential.

We have definitely started the ball rolling with this trip, in turn, it is one more exciting stage in the growth of ABS. The next few months will be an opportunity to continue that momentum and seek out new opportunities.